Article Details
Retrieved on: 2022-12-29 13:54:28
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer licensed SPK-9001 (fidanacogene elaparvovec), from Spark Therapeutics under a December 2014 agreement. Price Action: PFE shares are up 0.35% at ...
Article found on: www.benzinga.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here